Grünenthal Group
Zieglerstraße 6
52078 Aachen

Phone: +49 241 569-0

Contact Form

Adverse Drug Reaction Reporting



Innovating at Scale: Gabriel Baertschi Interview Economist Intelligence Unit

In an interview with the Economist Intelligence Unit our CEO talks about Grünenthal’s ambition, explains why it is necessary to go for a network based approach in R&D and what his concept of leadership is all about.

Grünenthal Clinical Trial Portal

Grünenthal Group

The Grünenthal Group

The Grünenthal Group is an entrepreneurial, science-based pharmaceutical company specialized in pain, gout and inflammation.

Our ambition is to deliver four to five new products to patients in diseases with high unmet medical need by 2022 and become a €2 billion company. We are a fully integrated research & development company with a long track record of bringing innovative pain treatments and state-of-the-art technologies to patients. By sustainably investing in our R&D above the industrial average, we are strongly committed to innovation.


Innovation Hub Boston

Grünenthal opens Innovation Hub in Boston as next step in strategy to drive external innovation in pain, specialty therapeutics and medical devices forward

Grünenthal, a worldwide leader in Pain, announced today that it has opened a new Innovation Hub in the Greater Boston area. Through this Innovation Hub, Grünenthal aims to identify promising projects in pain, inflammation, orphan diseases, and devices & technologies from the large number of projects in late discovery and early development in the region. By building collaborative networks, in close partnership with institutions in the Boston area – from entrepreneurial scientists to successful spin-outs and start-ups – Grünenthal will drive these projects through research and development (R&D) in order to address the need for innovation.


New CCO at Grünenthal

Mark Fladrich appointed new Chief Commercial Officer (CCO) at Grünenthal

The Grünenthal Group announced today that Mark Fladrich will take over the position as Chief Commercial Officer (CCO) responsible for the entire Global Commercial Organization. Currently Mark Fladrich is Area Vice President, Southern and Western Europe, at AstraZeneca, based in the UK. He will join Grünenthal effective September 1, 2017.
Mark Fladrich has almost 30 years of experience in the pharmaceutical industry, and more than 20 years at AstraZeneca. The 57 year old Australian by nationality brings a broad variety of expertise – from in-market knowledge to regional and global sales and marketing to Grünenthal.